Olanzapine (Zyprexa) vs Olanzapine (Zyprexa Relprevv)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Olanzapine (Zyprexa)

Marketed by Cheplapharm Arzneimittel GmbH and partners

Approved in Schizophreniasmall molecule
Partial signal

NCT03510325 · Phase 3 · completed

This trial randomly assigned 762 people with schizophrenia to active antipsychotic treatments, with outcomes rated by masked assessors but treatment assignment itself not blinded. Among 111 participants who had not responded to first-line treatment and were reassigned to a second drug, 31.7% responded on olanzapine against 44.7% on amisulpride and 62.5% on clozapine, a significant difference across the three (p=0.03). Olanzapine was the least effective of the second-line options tested.

Next expected readout: February 2027 · NCT03781115 (registry estimate)

Reported efficacy

Treatment efficacy rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months); All-cause dropout rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months): Phase 2 symptomatic response (≥40% PANSS reduction) among 111 first-episode-treatment nonresponders re-randomized to second-line therapy: olanzapine 31.7% (13/41) vs amisulpride 44.7% (17/38) vs clozapine 62.5% (20/32); chi-square=6.9, P=.03 (missed)

Result source: NCT03510325

Olanzapine (Zyprexa Relprevv)

Marketed by Cheplapharm Arzneimittel GmbH and partners

Approved in Schizophreniasmall molecule
Reliable signal

NCT00088478 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial of 402 patients. All three tested doses of the long-acting olanzapine injection produced a significantly greater reduction in psychiatric symptom severity (PANSS) than placebo.

Reported efficacy

Demonstrate superiority of IM olanzapine depot 300 mg/2 weeks, 405 mg/4 weeks, and 210 mg/2 weeks dosages compared with placebo in the treatment of patients with schizophrenia: 8-week acute study, olanzapine long-acting injection (210 mg/2wk, 300 mg/2wk, 405 mg/4wk) vs placebo: PANSS total score decrease significantly greater for all three LAI regimens vs placebo (p<.001 each). (met)

Result source: NCT00088478

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointOlanzapine (Zyprexa)Olanzapine (Zyprexa Relprevv)
PANSS total, change-8.8 vs 4.5−13.3 vs placebowk 4 · n 21NCT00686998—Not posted · NCT00088491
CGI-S, change—Not posted · NCT00083668-0.4 vs -0.3vs Oral Olanzapinewk 104 · n 121NCT00320489
PANSS response31.7% vs 44.7%avs amisulprideNCT03510325—Not posted · NCT00088491
PSP, change—Not posted · NCT00083668—Not posted · NCT00088491
Relapse (% of patients)—Not posted · NCT0008366820.1% vs 18.5%vs Oral Olanzapinen 264NCT00320489

PANSS total, change

Olanzapine (Zyprexa)
-8.8 vs 4.5−13.3 vs placebowk 4 · n 21NCT00686998
Olanzapine (Zyprexa Relprevv)
—Not posted · NCT00088491

CGI-S, change

Olanzapine (Zyprexa)
—Not posted · NCT00083668
Olanzapine (Zyprexa Relprevv)
-0.4 vs -0.3vs Oral Olanzapinewk 104 · n 121NCT00320489

PANSS response

Olanzapine (Zyprexa)
31.7% vs 44.7%avs amisulprideNCT03510325
Olanzapine (Zyprexa Relprevv)
—Not posted · NCT00088491

PSP, change

Olanzapine (Zyprexa)
—Not posted · NCT00083668
Olanzapine (Zyprexa Relprevv)
—Not posted · NCT00088491

Relapse (% of patients)

Olanzapine (Zyprexa)
—Not posted · NCT00083668
Olanzapine (Zyprexa Relprevv)
20.1% vs 18.5%vs Oral Olanzapinen 264NCT00320489
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety

Coverage. Olanzapine (Zyprexa): 11 of 11 rows · Olanzapine (Zyprexa Relprevv): 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricOlanzapine (Zyprexa)Olanzapine (Zyprexa Relprevv)
CGI-S
absolute change · score
No placebo or comparator arm
-0.17 score @ 313wka,b
NCT00088465 · Phase 3 · registry result, not featured evidence
-0.17 score @ 313wka,b
NCT00088465 · Phase 3 · registry result, not featured evidence
PANSS General Psychopathology
absolute change · score
No placebo or comparator arm
0.19 score @ 330wka,b
NCT00088465 · Phase 3 · registry result, not featured evidence
0.19 score @ 330wka,b
NCT00088465 · Phase 3 · registry result, not featured evidence
PANSS Negative
absolute change · score
No placebo or comparator arm
-0.08 score @ 330wka,b
NCT00088465 · Phase 3 · registry result, not featured evidence
-0.08 score @ 330wka,b
NCT00088465 · Phase 3 · registry result, not featured evidence
PANSS Positive
absolute change · score
No placebo or comparator arm
0.21 score @ 330wka,b
NCT00088465 · Phase 3 · registry result, not featured evidence
0.21 score @ 330wka,b
NCT00088465 · Phase 3 · registry result, not featured evidence
PANSS Total
absolute change · score
No placebo or comparator arm
0.3 score @ 330wka,b
NCT00088465 · Phase 3 · registry result, not featured evidence
0.3 score @ 330wka,b
NCT00088465 · Phase 3 · registry result, not featured evidence
QLS Total
absolute change · score
No placebo or comparator arm
6.75 score @ 330wka,b
NCT00088465 · Phase 3 · registry result, not featured evidence
6.75 score @ 330wka,b
NCT00088465 · Phase 3 · registry result, not featured evidence
SF-36 Physical Component Summary
absolute change · score
No placebo or comparator arm
Physical component summary
-0.36 score @ 329wka,b
Physical component summary
NCT00088465 · Phase 3 · registry result, not featured evidence
-0.36 score @ 329wka,b
Physical component summary
NCT00088465 · Phase 3 · registry result, not featured evidence
Dropout rate
63.4%Olanzapine/Intense Behavioral Weigc
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 14 more results
55.9%Olanzapine/Standard Behavioral Wei
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
38.2%
NCT00190749 · Phase 4 · registry result, not featured evidence
60.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
0%
NCT00797277 · Phase 3 · registry result, not featured evidence
22%Olanzapine
NCT00401973 · Phase 3 · registry result, not featured evidence
34.2%Olanzapine + Amantadine
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
31.5%Olanzapine + Metformin
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
18.2%
NCT00686998 · Phase 2 · registry result, not featured evidence
—Cohort 1: Olanzapine (Fast-D)
NCT06319170 · Phase 1 · registry result, not featured evidence
—Cohort 2: Olanzapine (To-be-market
NCT06319170 · Phase 1 · registry result, not featured evidence
—Cohort 3: Olanzapine (Slow-C)
NCT06319170 · Phase 1 · registry result, not featured evidence
—3 mg
NCT00512070 · Phase na · registry result, not featured evidence · combination
—0.3 mg
NCT00512070 · Phase na · registry result, not featured evidence · combination
—Olanzapine Only
NCT00512070 · Phase na · registry result, not featured evidence
54.9%c
NCT00320489 · Phase 3 · monotherapy
show 1 more result
60.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
14.9%Olanzapine/Intense Behavioral Weigc
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 14 more results
18.6%Olanzapine/Standard Behavioral Wei
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00190749 · Phase 4 · registry result, not featured evidence
8.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
—
NCT00797277 · Phase 3 · registry result, not featured evidence
4%Olanzapine
NCT00401973 · Phase 3 · registry result, not featured evidence
10.5%Olanzapine + Amantadine
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
5.5%Olanzapine + Metformin
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
4.5%
NCT00686998 · Phase 2 · registry result, not featured evidence
—Cohort 1: Olanzapine (Fast-D)
NCT06319170 · Phase 1 · registry result, not featured evidence
—Cohort 2: Olanzapine (To-be-market
NCT06319170 · Phase 1 · registry result, not featured evidence
—Cohort 3: Olanzapine (Slow-C)
NCT06319170 · Phase 1 · registry result, not featured evidence
—3 mg
NCT00512070 · Phase na · registry result, not featured evidence · combination
—0.3 mg
NCT00512070 · Phase na · registry result, not featured evidence · combination
—Olanzapine Only
NCT00512070 · Phase na · registry result, not featured evidence
9.8%c
NCT00320489 · Phase 3 · monotherapy
show 1 more result
8.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
Serious AEs
19.8%Olanzapine/Intense Behavioral Weigc
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 14 more results
12.7%Olanzapine/Standard Behavioral Wei
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
2.9%
NCT00190749 · Phase 4 · registry result, not featured evidence
18.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
0%
NCT00797277 · Phase 3 · registry result, not featured evidence
—Olanzapine
NCT00401973 · Phase 3 · registry result, not featured evidence
—Olanzapine + Amantadine
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
—Olanzapine + Metformin
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
0%
NCT00686998 · Phase 2 · registry result, not featured evidence
0%Cohort 1: Olanzapine (Fast-D)
NCT06319170 · Phase 1 · registry result, not featured evidence
3.2%Cohort 2: Olanzapine (To-be-market
NCT06319170 · Phase 1 · registry result, not featured evidence
0%Cohort 3: Olanzapine (Slow-C)
NCT06319170 · Phase 1 · registry result, not featured evidence
0%3 mg
NCT00512070 · Phase na · registry result, not featured evidence · combination
25%0.3 mg
NCT00512070 · Phase na · registry result, not featured evidence · combination
5.9%Olanzapine Only
NCT00512070 · Phase na · registry result, not featured evidence
9.5%c
NCT00320489 · Phase 3 · monotherapy
show 1 more result
18.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
c
somnolence 23.8%
weight increased 20.8%
headache 19.8%
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 14 more results
weight increased 30.4%
headache 18.6%
somnolence 18.6%
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
weight increased 16.2%
headache 10.3%
sedation 10.3%
NCT00190749 · Phase 4 · registry result, not featured evidence
weight increased 14.4%
anxiety 9.7%
insomnia 9.7%
NCT00088465 · Phase 3 · registry result, not featured evidence
drowsiness 8.1%
dizziness 2.7%
NCT00797277 · Phase 3 · registry result, not featured evidence
insomnia 10%
somnolence 8%
increased appetite 6%
NCT00401973 · Phase 3 · registry result, not featured evidence
somnolence 6.6%
dry mouth 5.3%
insomnia 5.3%
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 13.7%
somnolence 11%
nausea 6.8%
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
weight increased 40.9% (placebo 0%)
increased appetite 18.2% (placebo 2.4%)
somnolence 18.2% (placebo 2.4%)
NCT00686998 · Phase 2 · registry result, not featured evidence
injection site irritation 6.9%
injection site pain 6.9%
psychotic disorder 6.9%
NCT06319170 · Phase 1 · registry result, not featured evidence
injection site pain 9.7%
somnolence 9.7%
blood creatine phosphokinase increased 6.5%
NCT06319170 · Phase 1 · registry result, not featured evidence
alanine aminotransferase increased 6.5%
aspartate aminotransferase increased 6.5%
somnolence 6.5%
NCT06319170 · Phase 1 · registry result, not featured evidence
3 mg
abnormal lab values 33.3%
decreased appetite 16.7%
depression 16.7%
NCT00512070 · Phase na · registry result, not featured evidence · combination
0.3 mg
abnormal lab values 50%
depression 25%
psychotic symptoms 25%
NCT00512070 · Phase na · registry result, not featured evidence · combination
abnormal lab values 29.4%
insomnia/sleep disturbance 23.5%
diarrhea 17.6%
NCT00512070 · Phase na · registry result, not featured evidence
c
weight increased 16.7%
insomnia 11%
anxiety 9.8%
NCT00320489 · Phase 3 · monotherapy
show 1 more result
weight increased 14.4%
anxiety 9.7%
insomnia 9.7%
NCT00088465 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Olanzapine (Zyprexa)

BMI 3.64 kg @ 52wk
absolute change · kg
No placebo or comparator arm
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 3 more results
2.83 kg @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
3.36 kg @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
2.99 kg @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
CGI-I 2.04 score @ 52wk
absolute value · score
No placebo or comparator arm
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
2.29 score @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
Waist Circumference Change 7.22 cm @ 52wk
absolute change · cm
No placebo or comparator arm
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
7.31 cm @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
BPRS-C Total -28 score @ 52wk
absolute change · score
No placebo or comparator arm
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
-30.96 score @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
BPRS Total -1.98 vs -1.48 Risperidone score @ 12wk
absolute change · score
Total Score Change to Last Observation
NCT00190749 · Phase 4 · registry result, not featured evidence
CGI-S -0.22 vs -0.23 Risperidone score @ 12wk
absolute change · score
Change to last observation
NCT00190749 · Phase 4 · registry result, not featured evidence
PANSS-EC -10.2 vs -9.9 IM Haloperidol Plus Lorazepam score @ 0.0119wk
absolute change · score
NCT00797277 · Phase 3 · registry result, not featured evidence
ACES 2.14 vs 2.23 IM Haloperidol Pus Lorazepam score @ 0.0119wk
absolute change · score
NCT00797277 · Phase 3 · registry result, not featured evidence
Weight 2.76 kg @ 22wk
absolute change · kg
No placebo or comparator arm
NCT00401973 · Phase 3 · registry result, not featured evidence
show 2 more results
2.4 kg @ 22wk
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
0.65 kg @ 22wk
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
Fasting TG 0.33 mmol/L @ 22wk
absolute change · mmol/L
No placebo or comparator arm
Change from Baseline
NCT00401973 · Phase 3 · registry result, not featured evidence
show 2 more results
0.35 mmol/L @ 22wk
Change from Baseline
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
0.06 mmol/L @ 22wk
Change from Baseline
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
Total Cholesterol 0.36 mmol/L @ 22wk
absolute change · mmol/L
No placebo or comparator arm
Change from Baseline
NCT00401973 · Phase 3 · registry result, not featured evidence
show 2 more results
0.01 mmol/L @ 22wk
Change from Baseline
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
-0.08 mmol/L @ 22wk
Change from Baseline
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
HDL-C 0 mmol/L @ 22wk
absolute change · mmol/L
No placebo or comparator arm
Change from Baseline
NCT00401973 · Phase 3 · registry result, not featured evidence
show 2 more results
-0.11 mmol/L @ 22wk
Change from Baseline
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
-0.08 mmol/L @ 22wk
Change from Baseline
NCT00401973 · Phase 3 · registry result, not featured evidence · combination

+ 9 further endpoints in the CSV export.

Olanzapine (Zyprexa Relprevv)

Time to Discontinuation Any Reason Median 21.17 vs 22.26 Oral Olanzapine months
time to event · months
NCT00320489 · Phase 3 · monotherapy · converted to months from 644.5 days as posted
QLS Total 8.15 vs 7.24 Oral Olanzapine score @ 104wk
absolute change · score
NCT00320489 · Phase 3 · monotherapy
SF-36 Physical Component Summary 0.43 vs 0.84 Oral Olanzapine score @ 104wk
absolute change · score
Physical Score Detail Change Week 104 (n=124,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Physical Functioning 1.35 vs 2.44 Oral Olanzapine score @ 104wk
absolute change · score
Physical Functioning Change Week 104 (n=129,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 - Role Physical 10.7 vs 13.76 Oral Olanzapine score @ 104wk
absolute change · score
Role-Physical Change at Week 104 (n=130,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Bodily Pain 3.23 vs -0.6 Oral Olanzapine score @ 104wk
absolute change · score
Bodily Pain Change at Week 104 (n=131,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 General Health 2.69 vs 5.32 Oral Olanzapine score @ 104wk
absolute change · score
General Health Change at Week 104 (n=128,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Social Functioning 8.13 vs 5.1 Oral Olanzapine score @ 104wk
absolute change · score
Social Functioning Change at Week 104 (n=131,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Vitality 7.95 vs 9.01 Oral Olanzapine score @ 104wk
absolute change · score
Vitality Change at Week 104 (n=129,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 - Role Emotional 16.38 vs 17.59 Oral Olanzapine score @ 104wk
absolute change · score
Role-Emotional Change at Week 104 (n=129,134)
NCT00320489 · Phase 3 · monotherapy
EQ-5D 0.07 vs 0.09 Oral Olanzapine score @ 104wk
absolute change · score
NCT00320489 · Phase 3 · monotherapy
SUMD Total -0.72 vs -0.5 Oral Olanzapine score @ 104wk
absolute change · score
Total Score (Items 1-5) Change to Week 104
NCT00320489 · Phase 3 · monotherapy

+ 8 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olanzapine (Zyprexa)'s landscape · Olanzapine (Zyprexa Relprevv)'s landscape